Enterprise Value
263.1M
Cash
150.7M
Avg Qtr Burn
-21.84M
Short % of Float
0.43%
Insider Ownership
13.27%
Institutional Own.
37.89%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Libmeldy / OTL-200 (ex vivo autologous gene therapy) Details Rare diseases, Rare genetic disease, Metachromatic leukodystrophy Big Mover™ Suspected Mover™ Susp. Mover™ | PDUFA Approval decision | |
OTL-203 (ex vivo autologous gene therapy) Details Metabolic disorder, Mucopolysaccharidosis Type 1 | Phase 2 Data readout | |
OTL-201 (ex vivo autologous gene therapy) Details Metabolic disorder, Eye disease , Sanfilippo Syndrome, Mucopolysaccharidosis type IIIA | Phase 1/2 Update | |
OTL-103 (ex vivo autologous gene therapy) Details X-Linked severe combined immunodeficiency, Autoimmune disease | Failed Discontinued |